GMAB — Genmab A/S
Is GMAB overbought or oversold? Here is the current MarketMoodz read.
Genmab A/S (GMAB) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $51.57. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$51.57
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Genmab benefits from a diversified partnership and royalty model plus proprietary antibody platforms that provide multiple development and commercialization pathways. Recurring revenue from partnered products and a manageable cash runway reduce pure-play clinical exposure, while upcoming clinical/regulatory milestones offer upside catalysts. Competitive strengths include deep platform science and strong partner interest, but the company remains exposed to trial, partner and regulatory risk as well as sector sentiment shifts that favor large-cap defensive pharma. Near-term performance will hinge on milestone execution and partner program updates; medium-term upside depends on successful readouts, continued royalty growth and potential strategic interest in specialty franchises.
Key factors
- Established partnership and royalty model providing recurring revenue and downside protection versus pure clinical-stage peers
- Proprietary antibody engineering platforms (e.g., bispecific and enhanced Fc technologies) that support multiple programs and partnership interest
- Upcoming clinical and regulatory milestones in partnered and internal programs that could be meaningful catalysts
- Solid cash runway and disciplined R&D spend (relative to commercialization risk) that supports ongoing development
- Investor appetite for specialty/biopharma exposure and M&A/consolidation tailwinds in the sector that could increase strategic interest
- Limited direct exposure to recent large‑cap pharma defensive flows, but potential readthroughs from positive obesity/GLP‑1 data supporting broader biotech valuation reuse
Risks
- Clinical trial failures or delayed readouts for key programs leading to material share-price declines
- Concentration risk from reliance on a few large partners and royalty streams; adverse partner outcomes could materially reduce revenue visibility
- Regulatory setbacks or unfavorable labeling decisions for partnered products
- Intense competition from larger pharma companies and newer modalities that could limit commercial uptake and pricing power
- Macro and liquidity risk: rotation into large‑cap defensive pharma could temporarily depress mid‑cap biotech multiples
- Patent, IP or litigation risks that could impose costs or restrict commercialization
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for GMAB — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.